Cargando…
A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appro...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593077/ https://www.ncbi.nlm.nih.gov/pubmed/34236692 http://dx.doi.org/10.1007/s40487-021-00160-6 |
_version_ | 1784599634868436992 |
---|---|
author | Bazarbashi, Shouki Su, Wen-Pin Wong, Siew W. Singarachari, Ramanujam A. Rawal, Sudhir Volkova, Maria I. Bastos, Diogo A. |
author_facet | Bazarbashi, Shouki Su, Wen-Pin Wong, Siew W. Singarachari, Ramanujam A. Rawal, Sudhir Volkova, Maria I. Bastos, Diogo A. |
author_sort | Bazarbashi, Shouki |
collection | PubMed |
description | The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC. |
format | Online Article Text |
id | pubmed-8593077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-85930772021-12-02 A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries Bazarbashi, Shouki Su, Wen-Pin Wong, Siew W. Singarachari, Ramanujam A. Rawal, Sudhir Volkova, Maria I. Bastos, Diogo A. Oncol Ther Review The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC. Springer Healthcare 2021-07-08 /pmc/articles/PMC8593077/ /pubmed/34236692 http://dx.doi.org/10.1007/s40487-021-00160-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Bazarbashi, Shouki Su, Wen-Pin Wong, Siew W. Singarachari, Ramanujam A. Rawal, Sudhir Volkova, Maria I. Bastos, Diogo A. A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries |
title | A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries |
title_full | A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries |
title_fullStr | A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries |
title_full_unstemmed | A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries |
title_short | A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries |
title_sort | narrative review of implementing precision oncology in metastatic castration-resistant prostate cancer in emerging countries |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593077/ https://www.ncbi.nlm.nih.gov/pubmed/34236692 http://dx.doi.org/10.1007/s40487-021-00160-6 |
work_keys_str_mv | AT bazarbashishouki anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT suwenpin anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT wongsieww anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT singarachariramanujama anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT rawalsudhir anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT volkovamariai anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT bastosdiogoa anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT bazarbashishouki narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT suwenpin narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT wongsieww narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT singarachariramanujama narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT rawalsudhir narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT volkovamariai narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries AT bastosdiogoa narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries |